Learn More
  • B Barlogie, M Zangari, +5 authors G Tricot
  • Seminars in hematology
  • 2001
Thalidomide has recently been shown to have significant activity in refractory multiple myeloma (MM). A follow-up of the original phase II trial, expanded to 169 patients, shows 2-year survival of(More)
  • 1